Loading
A phase 1/2 trial of Olaparib in advanced solid tumours, run by Artios Pharma Ltd, now recruiting.
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) is a phase 1/2 interventional study registered as NCT05898399 by Artios Pharma Ltd, with 181 participants planned, started 2023-06-30 and due to reach its primary completion in 2028-06-30. Interventions recorded: ART6043 and Olaparib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PARP inhibitors, Olaparib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PARP inhibitors, Olaparib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PARP inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Olaparib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PARP inhibitors, Olaparib and the tag pipeline.
Shares PARP inhibitors, Olaparib and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/